Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study

Purpose To investigate antimicrobial use and primary and nosocomial infections in hospitalized COVID-19 patients to provide data for guidance of antimicrobial therapy. Methods Prospective observational cohort study conducted at Charité–Universitätsmedizin Berlin, including patients hospitalized with...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2022-12, Vol.50 (6), p.1441-1452
Main Authors: Lingscheid, Tilman, Lippert, Lena J., Hillus, David, Kruis, Tassilo, Thibeault, Charlotte, Helbig, Elisa T., Tober-Lau, Pinkus, Pfäfflin, Frieder, Müller-Redetzky, Holger, Witzenrath, Martin, Zoller, Thomas, Uhrig, Alexander, Opitz, Bastian, Suttorp, Norbert, Kramer, Tobias S., Sander, Leif E., Stegemann, Miriam S., Kurth, Florian
Format: Article
Language:English
Subjects:
Anti-Infective Agents - therapeutic use
Antiinfectives and antibacterials
Antimicrobial agents
C-reactive protein
Cohort analysis
Coinfection - drug therapy
Coinfection - epidemiology
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 Drug Treatment
Cross Infection - drug therapy
Cross Infection - epidemiology
Family Medicine
General Practice
Hemodialysis
Hospital Mortality
Hospitalization
Hospitals
Humans
Infectious Diseases
Internal Medicine
Mechanical ventilation
Medicine
Medicine & Public Health
Nosocomial infection
Nosocomial infections
Observational studies
Original Paper
Oxygenation
Patients
Procalcitonin
Prospective Studies
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To investigate antimicrobial use and primary and nosocomial infections in hospitalized COVID-19 patients to provide data for guidance of antimicrobial therapy. Methods Prospective observational cohort study conducted at Charité–Universitätsmedizin Berlin, including patients hospitalized with SARS-CoV-2-infection between March and November 2020. Results 309 patients were included, 231 directly admitted and 78 transferred from other centres. Antimicrobial therapy was initiated in 62/231 (26.8%) of directly admitted and in 44/78 (56.4%) of transferred patients. The rate of microbiologically confirmed primary co-infections was 4.8% (11/231). Although elevated in most COVID-19 patients, C-reactive protein and procalcitonin levels were higher in patients with primary co-infections than in those without (median CRP 110 mg/l, IQR 51–222 vs. 36, IQR 11–101, respectively; p  
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-022-01796-w